ARTICLE | Company News
CBMG acquires CAR T tech from China's PLAGH
February 10, 2015 1:50 AM UTC
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) jumped $2.29 (11%) to $23.40 on Monday after it said it will acquire chimeric antigen receptor (CAR) T cell therapies from the Chinese PLA General Hospital.
The deal includes CAR T therapies targeting CD19, CD20, CD30 and human epidermal growth factor receptor 1 ( EGFR1; HER1; ErbB1), as well as data from Phase I/II studies in unspecified indications. ...